Skip to content
value.today
Kiniksa Pharmaceuticals, Ltd. logo

Kiniksa Pharmaceuticals, Ltd.

🇧🇲 Hamilton, Bermuda, BermudaPharmaceuticalsFounded 2015

Kiniksa Pharmaceuticals, Ltd. is listed today as Kiniksa Pharmaceuticals, Ltd.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Kiniksa Pharmaceuticals, Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2019$9 MPrivate placement after listing$2 to $10 million

Kiniksa Pharmaceuticals, Ltd.: Private sale, Mar 2019

Investors in this round

10 investors had bought by the notice of Nov 23, 2020: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Kiniksa Pharmaceuticals, Ltd. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Bermuda

People named in the notice

  • Sanj K Patel · Executive Officer, Director
  • Thomas W Beetham · Executive Officer
  • Barry D Quart · Director
  • Felix J Baker · Director
  • G. Bradly D Cole · Director
  • Kimberly J Popovits · Director
  • Richard S Levy · Director
  • Stephen R Biggar · Director
  • Thomas R Malley · Director
  • Tracey L Mccain · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Please see Form 10-K filed on March 12, 2019”

Signed by Thomas W. Beetham, Executive vice president, chief legal officer. Newest notice filed Nov 23, 2020 (2 amendments). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Kiniksa Pharmaceuticals, Ltd., its revenue in fiscal 2024 came from these product and service lines: License and collaboration revenue $6.21 million (1%).

    Annual report (SEC XBRL) · Dec 2024

  • Kiniksa Pharmaceuticals, Ltd. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2020

Products and services#

No products or services of Kiniksa Pharmaceuticals, Ltd. are on record.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in Kiniksa Pharmaceuticals, Ltd.
InvestorKindAmountRoundRoleSource
667, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Baker Brothers Life Sciences LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Carsten BoessPersonnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Chris HeberligPersonnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Private Healthcare Fund I, LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Sanj K. PatelPersonnot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Stephen F. MahoneyPersonnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Thomas W. BeethamPersonnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Largest shareholders today

Institutions holding Kiniksa Pharmaceuticals, Ltd. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kiniksa Pharmaceuticals, Ltd.
NameRoleNamed in
Sanj K PatelExecutive officerNov 2020
Thomas W BeethamExecutive officerNov 2020
Chris K HeberligExecutive officerJul 2019
Barry D QuartDirectorNov 2020
Felix J BakerDirectorNov 2020
G. Bradly D ColeDirectorNov 2020
Kimberly J PopovitsDirectorNov 2020
Richard S LevyDirectorNov 2020
Sanj K PatelDirectorNov 2020
Stephen R BiggarDirectorNov 2020
Thomas R MalleyDirectorNov 2020
Tracey L MccainDirectorNov 2020

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.